Serina Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
SER$1.43+3.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(In thousands, except per share data)
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| REVENUES | ||
| License revenues | $— | $3,000 |
| Grant revenues | 56 | 153 |
| Total revenues | 56 | 3,153 |
| OPERATING EXPENSES | ||
| Research and development | 7,480 | 2,388 |
| General and administrative | 9,624 | 3,894 |
| Total operating expenses | 17,104 | 6,282 |
| Loss from operations | (17,048) | (3,129) |
| OTHER INCOME (EXPENSE), NET | ||
| Interest expense | (526) | (558) |
| Fair value inception adjustment on convertible promissory note | — | 2,240 |
| Change in fair value of convertible promissory notes | (7,017) | 5,356 |
| Change in fair value of warrants | 13,156 | 1,077 |
| Other income, net | 228 | 283 |
| Total other income, net | 5,841 | 8,398 |
| NET (LOSS) INCOME | (11,207) | 5,269 |
| Net loss attributable to noncontrolling interest | 66 | — |
| NET (LOSS) INCOME ATTRIBUTABLE TO SERINA THERAPEUTICS, INC. | $(11,141) | $5,269 |
| NET (LOSS) INCOME PER COMMON SHARE: | ||
| BASIC | $(1.51) | $2.36 |
| DILUTED | $(1.51) | $0.73 |
| WEIGHTED-AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: | ||
| BASIC | 7,359 | 2,235 |
| DILUTED | 7,359 | 7,351 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.